Kane Biotech's revyve® Wound Gel Validated in Peer-Reviewed Study
Event summary
- Kane Biotech's revyve® Antimicrobial Wound Gel featured in the International Wound Journal on February 20, 2026.
- Study demonstrates 99.99%–99.9999% reduction in bacterial counts within 30 minutes.
- Gel shows sustained in vitro activity for up to 7 days, potentially reducing dressing changes.
- Safety and non-cytotoxicity validated through biocompatibility testing and porcine wound-healing study.
The big picture
Kane Biotech's publication in the International Wound Journal provides third-party validation for its revyve® gel, addressing a critical gap in wound care where biofilms contribute to antibiotic resistance. This positions Kane Biotech to compete in a market increasingly focused on evidence-based solutions for chronic wounds. The study's findings could enhance the company's credibility with both clinicians and commercial partners, potentially accelerating adoption.
What we're watching
- Clinical Adoption
- How peer-reviewed validation will accelerate clinician and regulatory acceptance of revyve®.
- Commercialization Pace
- Whether sustained in vitro activity can drive market differentiation and reduce dressing change frequency.
- Strategic Partnerships
- The pace at which Kane Biotech can leverage this validation to secure new commercial partnerships.
Related topics